http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20200075860-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69ece09bafee7e0c49d1f7951a3faa2c |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70596 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2539-10 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57488 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate | 2018-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1de9427329f4090d5a8d5e520662390e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5fd6942a56e5bc19de08f815c6f41897 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ce8d7f50c60775589fc192d5e16a7f5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da64492c607d4b323b25ee1469b43cd1 |
| publicationDate | 2020-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20200075860-A |
| titleOfInvention | How to diagnose and treat cancer |
| abstract | The invention provides diagnostic methods for the treatment of cancer (e.g. bladder cancer (e.g. UC, e.g. mUC), kidney cancer, lung cancer, liver cancer, ovarian cancer, pancreatic cancer, colorectal cancer, or breast cancer), Methods of treatment, and compositions are provided. The present invention provides, at least in part, an expression level of one or more biomarkers described herein in a sample from an individual with cancer (eg, a PD-L1 axis binding antagonist such as an anti-PD-L1 antibody (eg (E.g. atezolizumab)) and anti-cancer therapies, including inhibitory substrate antagonists (e.g., TGF-β antagonists), how to identify individuals with cancer, which may benefit Methods for selecting a treatment regimen, methods for treating individuals with cancer, immunotherapy (e.g., PD-L1 axis binding antagonists such as anti-PD-L1 antibodies (e.g. atezolizumab)) and inhibitory substrates Anti-cancer therapies comprising antagonists (e.g., TGF-β antagonists), based on the discovery of methods for evaluating or monitoring a subject's response to treatment, and related kits, anti-cancer therapies, and uses do. |
| priorityDate | 2017-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 2380.